Parts of this study were previously presented as a poster presentation at the 71st Scientific Sessions of the American Diabetes Association, San Diego, CA, USA, 24–28 June, 2011, and at the 9th International Diabetes Federation Western Pacific Region Congress, Kyoto, Japan, November 24–27, 2012.
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study†
Version of Record online: 14 JUL 2013
© 2013 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Diabetes, Obesity and Metabolism
Volume 15, Issue 12, pages 1136–1145, December 2013
How to Cite
Inagaki, N., Kondo, K., Yoshinari, T., Maruyama, N., Susuta, Y. and Kuki, H. (2013), Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes, Obesity and Metabolism, 15: 1136–1145. doi: 10.1111/dom.12149
- Issue online: 5 NOV 2013
- Version of Record online: 14 JUL 2013
- Accepted manuscript online: 19 JUN 2013 12:30PM EST
- Manuscript Accepted: 11 JUN 2013
- Manuscript Revised: 4 FEB 2013
- Manuscript Received: 18 DEC 2012
- Mitsubishi Tanabe Pharma Corporation
- 1International Diabetes Federation. IDF Diabetes Atlas. 5th edn. Brussels, Belgium: International Diabetes Federation, 2011.
- 2American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care 2012; 35(Suppl 1): S11–63.
- 3Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203., , et al.
- 13Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669–672., , et al.
- 19Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2013; 15: 432–440., , et al.
- 202010., , , . The renal glucose threshold is increased in patients with type 2 diabetes: results from a novel method for measuring the renal threshold. 70th Scientific Sessions of the American Diabetes Association (Abstract 2186-PO). Orlando, FL, USA,
- 212011., , , , , . Mechanism of action: canagliflozin, an SGLT2 inhibitor, increases urinary glucose excretion (UGE) in ZDF rats by lowering the renal glucose threshold (RTG). 71st Scientific Sessions of the American Diabetes Association (Abstract 1090-P). San Diego, CA, USA,
- 222011., , . Exposure-response modeling of canagliflozin effects on the renal glucose threshold in subjects with type 2 diabetes (T2DM). 71st Scientific Sessions of the American Diabetes Association (Abstract 1072-P). San Diego, CA, USA,